Expression of Sox10 and c-kit in Sinonasal Mucosal Melanomas Arising in the Chinese Population

Head and Neck Pathology

Volumn 6, Issue 4, 2012, Pages 401-408

  Liu, Hong Gang ^a   Kong, Max Xiangtian ^c   Yao, Qian ^a   Wang, Shu Yi ^b   Shibata, Robert ^c   Yee, Herman ^c   Martiniuk, Frank ^c   Wang, Beverly Y ^d,e  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BETH ISRAEL MEDICAL CENTER   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

c kit; Immunohistochemistry; Sinonasal mucosal melanomas; Sox10; Tyrosine kinase inhibitor

Indexed keywords

SOX10 PROTEIN, HUMAN; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR SOX; TUMOR MARKER;

ADULT; AGED; ARTICLE; ASIAN; BIOSYNTHESIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; METABOLISM; MIDDLE AGED; MUCOSA; PARANASAL SINUS TUMOR; PATHOLOGY;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MIDDLE AGED; MUCOUS MEMBRANE; PARANASAL SINUS NEOPLASMS; PROTO-ONCOGENE PROTEINS C-KIT; SOXE TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84869492912     PISSN: 1936055X     EISSN: 19360568     Source Type: Journal    
DOI: 10.1007/s12105-012-0375-2     Document Type: Article

References (47)

1. Nonaka D, Chiriboda L, Rubin BP. SOX10: a pan-schwannian and melanocytic marker. Am J Surg Pathol. 2008; 32: 1291-8.
2. Thompson LD, Wieneke JA, Miettinen M. Sinonasal tract and nasopharyngeal melanomas: a clinicopathologic study of 115 cases with a proposed staging system. Am J Surg Pathol. 2003; 27: 594-611.
3. Younes MN, Myers JN. Melanoma of the head and neck: current concepts in staging, diagnosis, and management. Surg Oncol Clin N Am. 2004; 13: 201-29.
4. Penel N, Mallet Y, Mirabel X, et al. Primary mucosal melanoma of head and neck: prognostic value of clear margins. Laryngoscope. 2006; 116: 993-5.
5. Meleti M. leemans CR, de Bree R, et al. Head and neck mucosal melanoma: experience with 42 patients, with emphasis on the role of postoperative radiotherapy. Head Neck. 2008; 30: 1543-51.
6. Pandey M, Mathew A, Iype EM, et al. Primary malignant mucosal melanoma of the head and neck region: pooled analysis of 60 published cases from India and review of literature. Eur J Cancer Prev. 2002; 11: 3-10.
7. Papaspyrou G, Garbe C, Schadendorf D, et al. Mucosal melanomas of the head and neck: new aspects of the clinical outcome, molecular pathology, and treatment with c-kit inhibitors. Melanoma Res. 2011; 21: 475-82.
8. Gershon TR, Oppenhermer O, Chin SS, et al. Temporally regulated neural crest transcription factors distinguish neuroectodermal tumors of varying malignancy and differentiation. Neoplasia. 2005; 7: 575-84.
9. Potterf SB, Mollaaghababa R, Hou L, et al. Analysis of SOX10 function in neural crest-derived melanocyte development: SOX10-dependent transcriptional control of dopachrome tautomerase. Dev. Biol. 2001; 237: 245-57.
10. Kordes U, Cheng YC, Scotting PJ. Sox group E gene expression distinguishes different types and maturational stages of glial cells in developing chick and mouse. Brain Res Dev Brain Res. 2005; 157: 209-13.
11. Kelsch RN. Sorting out SOX10 functions in neural crest development. BioEssays. 2006; 28: 788.
12. Ramos-Herberth FI, Karamchandani J, Kim J, et al. SOX10 immunostaining distinguishes desmoplastic melanoma from excision scar. J Cutan Pathol. 2001; 37: 944-52.
13. Blochin E, Nonaka D. Diagnostic value of Sox10 immunohistochemical staining for the detection of metastatic melanoma in sentinel lymph nodes. Histopathology. 2009; 55: 626-8.
14. Jennings C, Kim J. Identification of Nodal Metastases in Melanoma Using Sox-10. Am J Dermatopathol. 2011; 33: 474-82.
15. Rivera RS, Nagatsuka H, Gunduz M, et al. c-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma. Virchows Arch. 2008; 452: 27-32.
16. Lennartsson J, Blume-Jensen P, Hermanson M, et al. Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor/c-kit mediated activation of Ras/MAP kinase pathway and c-fos induction. Oncogen. 1999; 18: 5546-53.
17. Lin SC, Liu CL, Wang TI, et al. Clinical implication of C-kit gene mutation in patients with large gastrointestinal stromal tumors. J Gastroenterol Hepatol. 2006; 21: 1604-8.
18. Handolias D, Hamilton AL, Salemi R, et al. Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. Br J Cancer. 2010; 102: 1219-23.
19. Clifton N. Harrison l, Bradley PJ, Jones NS. Malignant melanoma of nasal cavity and paranasal sinuses: report 24 patients and literature review. J Laryngol Otol. 2011; 125: 479-85.
20. Mori W. Geographic pathology of malignant melanoma in Japan. In: McGovem VJ, Russell P, editors. Pigment cell mechanism in pigmentation, vol. 1. Basel: Karger; 1973. p. 246-54.
21. Shah JP, Huvos AG, Strong EW. Mucosal melanomas of the head and neck. Am J Surg. 1977; 134: 531-5.
22. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base Report on cutaneous and non cutaneous melanoma. A summary of 84, 836 cases from the past decade. Cancer. 1998; 83: 1664-78.
23. Wagner M, Morris CG, Werning JW, et al. Mucosal melanoma of the head and neck. Am J Clin Oncol. 2008; 31: 43-8.
24. Patrick RJ, Fenske NA, Messina JL. Primary mucosal melanoma. J Am Academy Dermatol. 2007; 56: 828-34.
25. Morris LG, Wen YH, Nonaka D, et al. melanocytic marker in immunohistochemical evaluation of primary mucosal melanoma of the head and neck. Head Neck. 2008; 30: 771-5.
26. Jiao Z, Zhang ZG, Hornyak TJ, et al. Dopachrome tautomerase (Dct) regulates neural progenitor cell proliferation. Dev Biol. 2006; 296: 396-408.
27. Prasad ML, Jungbluth AA, Iversen K, Huvos AG, Busam KJ. Expression of melanocytic differentiation markers in malignant melanomas of the oral and sinonasal mucosa. Am J Surg Pathol. 2001; 25: 782-7.
28. Yu CH, Chen HH, Jeng YM, et al. HMB-45 may be a more sensitive marker than S100 or Melan-A for immunohistochemical diagnosis of primary oral and nasal mucosa melanomas. J Oral Pathol Med. 2005; 34: 540-5.
29. Shin J, Vincent JG, Cuda JD, et al. Sox10 is expressed in primary melanocytic neoplasms of various histologies but not in fibrohistiocytic proliferations and histiocytoses. J Am Acad Dermatol. 2012; Feb 9. [Epub ahead of print]. PMID: 22325460.
30. Went PT, Dirnhofer S, Bundi M, et al. Prevalence of KIT expression in human tumors. J Clin Oncol. 2004; 22: 4514-22.
31. Willmore-Payne C, Holden JA, Tripp S, et al. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis. Hum Pathol. 2005; 36: 486-93.
32. Willmore-Payne C, Holden JA, Hirshowitz S, et al. BRAF and c-kit gene copy number in mutation-positive malignant melanoma. Hum Pathol. 2006; 37: 520-7.
33. Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melamoma. J Clin Oncol. 2006; 24: 4340-6.
34. Antonescu CR, Busam KJ, Francone TD, et al. L567P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer. 2007; 121: 257-64.
35. Beadling C, Jacobson-Dunlop E, Hodi FS, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res. 2008; 14: 6821-8.
36. Satzger I, Schaefer T, Kuettler U, et al. Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas. Br J Cancer. 2008; 99: 2065-9.
37. Ashida A, Takata M, Murata H, et al. Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas. Int J Cancer. 2009; 124: 862-8.
38. Torres-Cabala CA, Wang WL, Trent J, et al. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol. 2009; 22: 1446-56.
39. Woodman SE, Davies MA. Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol. 2010; 80: 568-74.
40. Chute DJ, Cousar JB, Mills SE. Anorectal malignant melanoma: morphologic and immunohistochemical features. Am J Clin Pathol. 2006; 126: 93-100.
41. Alexis BJ, Martinez AE, Lutzky J. An immunohistochemical evaluation of c-kit (CD117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients. Melanoma Res. 2005; 15: 283-5.
42. Medina JE, Ferlito A, Pellitteri PK, et al. Current management of mucosal melanoma of the head and neck. J Surg Oncol. 2003; 83: 116-22.
43. Patel SG, Prasad ML, Escrig M, et al. Primary mucosal malignant melanoma of the head and neck. Head Neck. 2002; 24: 247-57.
44. Gavriel H, McArthur G, Sizeland A, et al. Review: mucosal melanoma of the head and neck. Melanoma Res. 2011; 21: 257-66.
45. Fiorentini G, Rossi S, Lanzanova G, et al. Tyrosine Kinase inhibitor imatinib mesylate as an anticancer agent for advanced ocular melanoma expressing immunohistochemical C-KIT (CD117): preliminary results of a compassionate use clinical trail. J Exp Clin Cancer Res. 2003; 22: 17-20.
46. Ivan D, Niveiro M, Diwan AH, et al. Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec). J Cutan Pathol. 2006; 33: 280-5.
47. Lefevre G, Glotin AL, Calipel A, et al. Roles of stem cell factor/c-kit and effects of Glivec/STI571 in human uveal melanoma cell tumorigenesis. J Biol Chem. 2004; 279: 31769-79.